TABLE 1.

Intracellular cytokine expression by CD3⁺ T cells following anti-SP and anti-F prophylactic antibody treatment prior to RSV infection^a

Day	Cytokine	Total cytokine-expressing CD3+ BAL (103) ± SEMb
		nIg	anti-SP	% Reductionc	anti-F	% Reduction	anti-SP/F	% Reduction
3	IL-2	13.7 ± 4.2	3.8 ± 0.5	72	9.0 ± 1.5	34	4.8 ± 1.7	65
	IL-4	13.0 ± 4.0	3.8 ± 0.5	70	8.2 ± 1.3	37	4.5 ± 1.6	65
	IL-5	12.7 ± 3.9	4.2 ± 0.6	67	9.5 ± 1.6	25	5.3 ± 1.8	58
	IL-10	8.8 ± 2.7	2.2 ± 0.3	75	5.5 ± 0.9	38	2.5 ± 0.9	72
	IFN-γ	16.2 ± 5.0	5.1 ± 0.7	69	11.4 ± 1.9	30	6.4 ± 2.2	60
	TNF-α	19.3 ± 5.9	6.3 ± 0.9	67	15.6 ± 2.6	19	8.5 ± 3.0	56
5	IL-2	17.3 ± 5.5	2.2 ± 0.4	87	11.6 ± 1.4	33	4.9 ± 1.5	72
	IL-4	16.9 ± 5.4	2.5 ± 0.5	85	11.1 ± 1.3	34	5.5 ± 1.7	67
	IL-5	18.2 ± 5.8	2.8 ± 0.5	85	12.3 ± 1.4	32	6.6 ± 2.0	64
	IL-10	12.7 ± 4.1	1.8 ± 0.3	86	9.1 ± 1.1	28	4.0 ± 1.2	69
	IFN-γ	19.3 ± 6.1	3.1 ± 0.6	84	15.1 ± 1.8	22	6.4 ± 2.0	67
	TNF-α	27.8 ± 8.9	5.0 ± 0.9	82	20.2 ± 2.4	27	8.6 ± 2.6	69
7	IL-2	12.0 ± 3.0	4.8 ± 1.0	60	6.1 ± 0.6	49	6.7 ± 2.7	44
	IL-4	10.6 ± 2.7	4.0 ± 0.9	62	5.5 ± 0.5	48	6.4 ± 2.6	40
	IL-5	8.9 ± 2.3	4.6 ± 1.0	48	7.0 ± 0.7	21	6.6 ± 2.7	26
	IL-10	4.5 ± 1.1	2.5 ± 0.6	44	4.0 ± 0.4	11	3.8 ± 1.5	16
	IFN-γ	10.3 ± 2.6	5.4 ± 1.2	48	7.6 ± 0.7	26	7.6 ± 3.0	26
	TNF-α	21.2 ± 5.4	9.7 ± 2.1	54	3.8 ± 1.3	82	12.8 ± 5.2	40

^aBALB/c mice were treated with control nIg, anti-SP, anti-F, or anti-SP/F antibodies 24 h prior to RSV infection. BAL samples from three mice per group were examined on days 3, 5, and 7 p.i. The results of three independent experiments are shown.

^bData are represented as total CD3⁺ BAL expressing IL-2, -4, -5, or -10, IFN-γ, or TNF-α per lung ± SEM. The total number of CD3⁺ BAL expressing a particular cytokine was determined by multiplying the total number of BAL by the percent CD3⁺ cells expressing that cytokine.

^cPercent reduction is the change in total cytokine-expressing CD3⁺ cells after anti-SP, anti-F, or anti-SP/F treatment relative to total cytokine-expressing CD3⁺ cells after nIg treatment.